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Role of renal endopeptidase 24.11 in kinin metabolism in vitro and in
vivo. The relative contributions of three kininases to total urinary
kininase activity were determined by measuring the hydrolysis of kinins
in the presence and absence of inhibitors of kininase I (2-mercapto-
methyl-3-guanidinoethylthiopropanoic acid; MGTA), kininase II (cap-
topril) and neutral endopeptidase 24.11 (NEP or enkephalinase A;
phosphoramidon). Surprisingly, NEP was responsible for 68 2% (N =
18) of the total kininase in the rat while kininase I and II contributed
only 9 0.4% and 23 1%, respectively. To study the effects of NEP
inhibition on renal function, phosphoramidon (110 or 330 p.glhrlkg; N =
6) or saline (0.1 d/min; N = 6) was infused into rats. Urinary kinins,
kininases, renal blood flow (RBF), glomerular filtration rate (GFR),
UNaV, UKV and UV were measured during control, experimental and
recovery periods. Phosphoramidon at the higher dose decreased total
urinary kininase activity from 284 49 to 58 5 ng/min/kg (77%, P <
0.01), and increased kinin excretion from 74 9 to 128 21 pg/mm/kg
(73%, P < 0.02), UV from 72 10 to 82 10 ilIminIkg (15%, P < 0.01)
and UNaV from 12 2 to 17 3 EqImin/kg (37%, P < 0.02), while BP,
RBF, GFR and UKV did not change. '251-Tyr°-bradykinin infused into
the aorta did not appear in the urine intact during simultaneous
phosphoramidon and captopril adminstration. This is the first demon-
stration of NEP having a major role in the catabolism of kinins. The
increase in UNaV and UV after phosphoramidon administration may be
due to the inhibition of intrarenal kinin destruction.
The renal kallikrein—kinin system has been implicated in the
regulation of water and sodium excretion as well as in the
pathophysiology of some forms of hypertension [1—3]. Although
in some studies urinary kinins were measured, in most of them
kallikrein excretion was the only component of the system
determined [2, 4—6], as it was assumed to reflect changes in the
intrarenal concentration of kinins. However, kinins are rapidly
metabolized by enzymes collectively called kininases [7] and
both renal tissue and urine contain such kininases [7—10]. Thus,
the intrarenal concentration of kinins may depend on both
production and destruction of this peptide. Three major urinary
enzymes were the subject of this investigation. Urine contains
a kininase I or carboxypeptidase N-type enzyme which cleaves
the C-terminal arginine [7, 9]. Kininase II (angiotensin I con-
verting enzyme) [7, 8] and the neutral endopeptidase 24.11
(NEP; enkephalinase A) [11] are also present in the urine. Both
inactivate kinins by releasing the C-terminal Phe-Arg. Here we
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report the contribution of the three kininases to kinin inactiva-
tion in rat urine in vitro and the effect of their inhibitors on
urinary kinin excretion and on renal functions in vivo. Unex-
pectedly, about one—half to two—thirds of the total activity in rat
urine can be attributed to NEP, and the inhibition of this
enzyme in vivo increased kinin excretion. We believe that this
is the first demonstration that NEP participates in kinin catab-
olism in vivo [12].
Methods
Studies in vitro
Rats were infused with saline (0.1 to 0.2 mi/mm) for approx-
imately one hour, and urine was collected through a catheter in
the ureter. The urine was then desalted on a Sephadex G-25 fine
(Pharmacia Inc., Piscataway, New Jersey, USA) column. Twenty
1 of a desalted urine sample and 60 pi of 0.1 M Tris buffer (pH
7.2) were mixed in a polypropylene tube, and preincubated at
37°C. Prewarmed 2.5 j.g of synthetic bradykinin (Bachem,
Torrance, California, USA) in 20 1 of assay buffer was added
to each tube to initiate the reaction. The mixture was incubated
for 10 to 40 minutes at 37°C. The reaction was terminated by the
addition of 300 pi of an assay buffer containing 20 mM EDTA
and 2 miu I, lO-phenanthroline (Fisher Scientific Company, Fair
Lawn, New Jersey, USA). For the assessment of the contribu-
tion of each enzyme to the total kininase activity, the following
specific inhibitors were added to the incubation mixture prior to
preincubation: 10 M 2-mercaptomethyl-3-guanidinoethyl-thio-
propanoic acid (MGTA; Calbiochem—Behring, La Jolla, Cali-
fornia, USA) to inhibit un-nary kininase I-type carboxypepti-
dase; 10 M captopril (Squibb Institute, Princeton, New Jersey,
USA) to inhibit kininase II; and 1 LM phosphoramidon (Peptide
Institute—Protein Research Foundation, Osaka, Japan) to in-
hibit NEP.
The amount of kinin in the reaction mixture was determined
by RIA [13, 14]. Total urinary kininase activity was calculated
from the difference in the amount of kinin in the inhibited (15
mM EDTA + 1.5 mrt 1, lO-phenanthroline) and uninhibited
reaction tubes. This combination of EDTA and 1, lO-phenan-
throline inhibited the total kininase activity. Kininase I, II or
NEP activity was calculated by subtracting the value found in
tubes containing MGTA, captopril or phosphoramidon from the
amount of bradykinin inactivated in absence of inhibitors at set
time intervals. The antibodies to bradykinin used in the radio-
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immunoassay do not have cross—reactivity with des-Arg9-
bradykinin nor with des-Phe8-Arg9-bradykinin [15]. The activ-
ity of the kininases between pH 6.0 to 8.5 was established by
adjusting the pH of 0. 1M Tris HCI accordingly.
In preliminary studies, we found that the kininase activity
was stable in stored rat urine at 4°C for at least one month,
while the activity diminished after repeated freezing and thaw-
ing. Consequently, urine was stored at 4°C. The intra- and
inter-assay errors in assaying total kininase activities were 5.5%
(N = 5) and 7.8% (N = 5).
Studies in vivo
Experiments were carried out on male Sprague—Dawley
(S-D) rats (Charles River, Wilmington, Massachusetts, USA)
weighing 250 to 365 g. Food was withheld for 12 hours before
the study, but water was administered ad libitum.
To evaluate the role of NEP, we examined the effects of the
NEP inhibitor, phosphoramidon, on urinary kinin excretion and
renal function. Rats were anesthetized with intraperitoneal
sodium pentobarbital (50 mg/kg) with supplemental doses given
when necessary to maintain an even plane of anesthesia. A
heating pad adjusted to 37°C was placed beneath the rats to
maintain body temperature, and the trachea was cannulated
with the rats allowed to breathe spontaneously. Both femoral
arteries were catheterized (PE-50, Clay—Adams, Parsippany,
New Jersey, USA) for monitoring blood pressure and blood
sampling. Both femoral veins were catheterized (PE-50) for
infusion of test solutions and for supplemental pentobarbital
administration. After a midline abdominal incision, both ureters
were isolated and catheterized with PE-10 tubing, taking special
care to minimize trauma to the ureter. The presence of blood in
urine was assessed by Multistix (Ames Division, Miles Labo-
ratories, Inc., Elkhart, Indiana, USA), and only rats where
blood was absent from the urine were included in these studies.
Following surgery, after a priming dose of inulin (Difco, Detroit,
Michigan) and p-aminohippuric acid (PAH; Aldrich Chemical
Co., Inc., Milwaukee, Wisconsin, USA) was administered, a
constant infusion of inulin and PAH was started. The experi-
ments were carried out after one hour of stabilization. The
experiments lasted three hours and consisted of two control (0
to 30 and 30 to 60 mm), two experimental (60 to 90 and 90 to 120
mm) and two recovery (120 to 150 and 150 to 180 mm) periods.
During each 30 minute period, urine from each kidney was
collected in a tube containing 0.5 ml mineral oil or pepstatin
HCI (200 ng/5 pl Protein Res. Found.). At the midpoint of each
urine collection, a blood sample (0.3 ml) was drawn for hema-
tocrit and for measurement of inulin and PAH. During the
experiments all animals were infused with 0.15 M NaCl at a rate
of 0.1 mllmin. Group I (time control, N = 6) received a constant
infusion of 0.15 M NaC1 throughout the experiment, Groups II
and III (N = 6 in each group) received a continuous infusion of
110 or 330 pg/hr/kg of phosphoramidon, respectively. Group IV(N = 6) received a continuous infusion of 2 mg/hr/kg of
captopril. In this group, there was no recovery period. All the
drugs were dissolved in 0.15 M NaC1 and infused at the same
rate as in Group I.
To determine whether filtered kinins appear intact in urine
during kininase inhibitor administration, we infused '251-Tyr°-
bradykinin into the aorta above both renal arteries in rats
treated with phosphoramidon and/or captopril, and measured
the binding of radioactivity in the urine to an excess of kinins'
antibody. For this, a PE-lO tube was placed into the abdominal
aorta via the left femoral artery above both renal arteries to
inject '2I-Tyr°-bradykinin (Protein Res. Found.).
After a one—hour stabilization period, experiments consisting
of one control (0 to 30 minutes) and three experimental (30 to
40, 40 to 50 and 50 to 60 mm) periods were carried out. During
each period, urine was collected in pepstatin HC1. Three groups
of rats were studied. Group V (N = 4) received a continuous
infusion of 330 pg/hr/kg phosphoramidon with 0.15 M NaC1 at a
rate of 0.1 mI/minute. Group VI (N = 4) received a constant
infusion of 2 mg/hr/kg captopril with 0.15 M NaCl. Group VII (N
4) received a constant combined infusion of both 330 pg/hr/kg
phosphoramidon and 2 mg/hr/kg captopril, with 0.15 M NaC1.
All three groups received a bolus injection of 12I-Try°-brady-
kinin (6 x 106 c.p.m.) at the beginning of the first experimetital
period.
Analytical methods
Urine volume was determined gravimetrically. The pH of
samples collected under mineral oil was measured with a
microelectrode. Urinary sodium and potassium were measured
with an autoanalyzer. Inulin and PAH concentrations in urine
and plasma were measured by standard techniques [16, 17], and
urinary kinins by RIA [13, 14]. Urinary kininase activities were
measured as described above. In groups V, VI and VII the
presence or absence of intact 125I-Tyr°-bradykinin was estab-
lished by determining whether or not an excess of kinin
antibody bound the radioactivity.
Calculations and statistics
GFR and RBF were estimated by the clearance of inulin and
PAH, respectively, and expressed per single kidney [18]. All
values were estimated for the function of a single kidney.
Values were normalized per kg body weight and are presented
as mean 1 SEM.
A mean value of each variable was calculated for the control,
experimental and recovery periods for each rat. Paired t-tests
with a Bonferroni adjustment to the alpha level (0.05/# of tests)
were used to determine changes in measured variables between
control and infusion periods. The Bonferroni adjustment was
used to maintain the overall significance level of the tests at 0.05
and take into account the four separate within—group compari-
sons. The experiments were designed to test whether the
experimental period exceeded the control period (one—sided
test). The alpha level of the test was then 0.05/4 = 0.0125.
Analysis of variance (ANOVA) was used to determine the
significance of the delta changes (control vs. experimental
periods) among groups. Where a difference among groups was
detected, pairwise comparisons were made using Tukey's method
to adjust the alpha level of the test for the multiple comparisons.
Results
Studies in vitro
Rat urine samples rapidly inactivated the added bradykinin as
determined by RIA. A relationship was found between the
decrease in the amount of kinin remaining in the samples with
the volume of urine added (Fig. 1A) and with the length of
incubation (Fig. 1B). The inactivation of kinins proceeded
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decrease in the inactivation of kinins should reflect their ratio of
activities in rat urine (Fig. 3).
NEP was responsible for 68 2% of the total urinary
kininase activity, while kininase I and II contributed only 9
.04 and 23 1% in 18 male rats (Fig. 4). In three female S-D
rats, the relative contribution of these kininases was 64 1, 13
1 and 22 0.4%, respectively.
Because of differences in km values of bradykinin with the
three enzymes, kininase activities were also determined at
different peptide concentrations which varied from 2.36 flM to
23.6 M. However, even at the lowest substrate concentration
approaching physiological concentration, most of the kininase
activity was due to NEP as the inhibition by phosphoramidon
decreased only from 74 to 53%. The inhibition by captopril, on
I ' the other hand, increased from 18 to 38% when the bradykinin
10 20 30 40 50 concentration was lowered to 2.4 n (Table 1).
Incubation time, mm
Studies in vivo
(N = 5)
0
Fig. 1. Decrease in kinin concentration during incubation with increas-
ing amounts of urine for 20 minutes (A), and during incubation with 20
/.sJ urine for 10 to 50 minutes (B). Closed circles and vertical bars
represent the mean SEM.
optimally at pH 7.2, and decreased to 70% at pH 6.0. When 20
,.d of urine was incubated with increasing amounts of bradyki-
nm, the hydrolysis of bradykinin increased linearly and reached
a plateau at 2.5 of added bradykinin (Fig. 2). Kinin concen-
tration did not change significantly during incubation for 120
minutes in the presence of EDTA and 1, lO-phenanthroline,
indicating that urinary kallikrein did not generate any significant
amount of kinin from an endogenous kininogen at least in two
hours, and that EDTA (7.5 to 30 mM) and 1, lO-phenanthroline
(0.75 to 3 mM) blocked the rat urinary kininase activity com-
pletely (Fig. 3). On the other hand, either MGTA (2.5 to 20 SM),
captopril (2.5 to 20 tM) or phosphoramidon (0.1 to 10 /.tM)
inhibited urinary kininases only partially. The combination of
MGTA, captopril and phosphoramidon blocked the activity
almost completely. As these specific inhibitors inhibit their
respective enzymes at the concentrations used, the percent
The observed results for Groups I through IV are given in
Table 2. In the control group, none of the parameters changed
significantly during experimental and recovery periods, with the
exception of the hematocrit which decreased significantly.
During the infusion of phosphoramidon to groups II and III, the
urinary kininase activities decreased and urinary kinin excre-
tion, UNaV and UV increased significantly, while UKV, GFR
and RBF remained unchanged. Phosphoramidon inhibited NEP
(95%), but to a lesser degree also kininase I and II and
continued to inhibit kininases during the recovery period.
During the infusion of captopril, urinary total kininase, kininase
II and NEP activities decreased (15%, 30% and 16%), and
urinary kinin excretion and UNaV increased (Table 2). How-
ever, these changes were small compared to those found after
the phosphoramidon infusion (Table 2), and most of them were
not statistically significant.
To determine whether filtered kinins contribute to the phos-
phoramidon—induced increase in kinin excretion, we infused
approximately 10 ng of the decapeptide 125I-Tyr°-bradykinin
into the aorta above both renal arteries in rats treated with
phosphoramidon and/or captopril, and measured the amount of
intact tracer excreted in the urine. In groups V, VI and VII,
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urine samples were highly radioactive throughout the whole
experimental period (Group V: 7.4 0.2 x i05 C.P.M.; Group
VI: 6.5 0.5 x lO C.P.M,; and Group VII: 7.5 0.5 x IO
C.P.M.), but the radioactivity did not bind to an excess of
bradykinin antibody, showing that no intact radiolabeled brady-
kinin was excreted. When '261-Tyr°-bradykinin was added di-
rectly to the urine, the antibody bound 70 to 80% of the
radioactivity.
Discussion
Table 1. Effect of kininase inhibitors on total
various bradykinin concentrations (N = 10
kininase activity at
urine samples)
MGTA CaptoprilBradykinin
concentrations 1O/.M
.
Phosphoramidon
1/2M
2.36 flM 11.2 1.1 38.0 1.7 53.4 1.6
23.60 flM 10.6 0.9 34.9 1.4 55.4 1.3
236.00 nM 9.9 1.2 30.4 1.9 60.4 1.9
2.36 /.SM 8.5 0.7 22.3 1.4 68.1 1.7
23.60 /.LM 7.5 0.4 18.2 1.8 73.7 2.2
[19]; however, the technique employed has some limitations.
First, human male urine was collected by spontaneous voiding
and it could be contaminated with kininase II and also by NEP
originating from the genital tract [20]. Second, kininase I
activity was calculated by subtracting the value of kininase II
from that of the total kininase. But human and animal kidney
are rich in NEP [21—23] which also has been called "kininase II
1/2" [24]. In the present study, we used only urine collected
from the ureters and the activities of kininase I, II and NEP
were distinguished by employing specific inhibitors. Here we
refer to the urinary carboxypeptidase—type activity as kininase
I, although many of the essential properties of urinary carboxy-
peptidase differ from plasma carboxypeptidase N which is
usually called kininase I [7, 9].
The two unexpected facts which emerge from these studies
are: 1) NEP, in spite of the fact that bradykinin has a relatively
high km in vitro (120 lM in man and 92 in hog) [22, 25], has a
major role in kinin metabolism in rat urine; and 2) inhibition of
NEP in vivo enhances kinin excretion and concurrently UV and
UNaV.
The inactivation of bradykinin in rat urine was shared by a
carboxypeptidase—type enzyme, kininase II and by NEP. At
kinin concentrations ranging from 2.36 n to 23.6 /LM, phos-
phoramidon inhibited 53 to 74%. Phosphoramidon is an inhibi-
tor of the metalloprotease thermolysin and NEP [21]. Urine
contains NEP, and it was partially purified from human urine
[11]; possibly this enzyme originates from the brush border of
the proximal tubules. This tissue is rich in both kininase II [7]
and NEP [21—23]. Immunocytochemical electronmicroscopy
indicated that NEP concentration is comparable to or higher on
the brush border of human kidney than that of kininase II [11].
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Fig. 3. The effects of increasing
concentration of kininase inhibitors on the
urinary kininase activity. 1) MGTA; 2)
captopril; 3) phosphoramidon; 4) MGTA,
captopril and phosphoramidon; and 5) EDTA
plus 1,10-phenanthroline. Closed circles and
vertical bars represent the mean 1 SEM
(N = 5).
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Results are expressed as percent inhibition of total kininase activity.
Fig. 4. Relative contributions of kininase 1, kininase II and neutral
endopepridase (NEP) to total urinary kininase activity. Opened circles
and vertical bars represent the mean and SEM, respectively (N = 18).
Rats were fasted for 12 hours and then infused with saline at a rate of 0.1
mI/mm during one hour of urine collection.
Previously one of us reported a method to measure human
urinary kininase I and II activities with bradykinin as substrate
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69.9 6.6
72.7 8.8
77.0 7.0
49.4 1.0
47.9± l.la
47.1 0.9
5.51 0.15
5.54 0.09
5.63 0.15
14.2 1.6
14.5 2.1
14.2 1.6
4.9 0.4
5.1 0.4
4.9 0.5
5.0 0.2
5.0 0.2
5.1 0.2
20.3 1.3
19.0 0.6
19.4 0.9
72.9 9.1
71.0 10.4
74.7 11.4
349.2 38.2
344.9 35.9
334.3 40.3
30.3 2.2
32.2 3.5
31.9 2.7
78.1 9.7
74.9 9.1
70,9 9.1
237.1 27.9
237.1 24.8
222.3 28.7
74.7 6.8
92.4 53a,b
86.0 8.8
48.0 0.8
46.8 0.6
46.1 0.7
5.41 0.14
5.59 0.13
5.81 0.17
13.5 1.7
17.8 20a,b
16.5 2.0
4.8 0.5
5.0 0.5
4.6 0.7
5.2 0.2
5,4 0.3
5.2 0.2
20.7 1.3
21.4 1.1
19.1 1.0
69.8 10.3
99.7 ii.r
93.1 8.9
313.2 49.0
83.0 142a.b
95.3 15.5
27.8 2.5
16.1 20a,b
14.0 1.2
67.8 8.8
38.4 47a,b
36.8 5.5
215.0 41.5
28.7 90a,b
44.0 9.6
72.2 11.0
82.0 11.3
90.6 12.1
45.9 1.3
44.6 l.4a
43.8 1.5
5,43 0.08
5.49 0.08
5.70 0.15
12.4 2.3
16.5
15.5 2.6
4.8 0.5
5.1 0.5
4.7 0.4
5.0 0.2
5.2 0.3
5.3 0.3
17.7 1.2
18.9 16b
17.0 1.1
73.5 9.5
127.9 227a.b
125.8 26.3
284.1 53.4
57,9
60.0 5.2
27.1 5.4
10.1 1.4
61.2 9.6
37.6 4.4
35.2 4.0
197.3 41.1
9,3 i,s
15.5 2.4
103.7 10.6
112.5 7.4
46.4 0.7
45.1 0.7k
5.47 0.05
5.60 0.12
22.5 1.5
25.0 1.6
4.5 0.2
4.8 0.4
5.6 0.2
5.5 0.2
21.1 1.3
21.6 1.5
71.8 9.4
80.7 10.9C
219.2 28.1
186.7 21.1C
17.1 2.7
17.7 34C
48.0 6.0
34,3 s.oa
159.6 24.9
134.6 16.1C
Although ACE and NEP cleave bradykinin at the same peptide
bond and release C-terminal Phe-Arg, all their essential prop-
erties including inhibition pattern, substrate specificity, antige-
nicity and molecular weight are different [7, 20, 21, 25]. The rat
kidneys differ from other species because they have relatively
little ACE [7]. The turnover number of bradykinin with human
renal NEP is very high, but because of its relatively high km
[221 its specificity constant (kcat/km) is lower than that with
kininase II. In the pig the specificity constant of bradykinin with
purified NEP is higher than that of enkephalin, although NEP is
frequently referred to as "enkephalinase A" [21]. No equiva-
lent data are available for the rat enzyme, but even when the
concentration of the bradykinin was lowered 10,000-fold, from
23.6 /M to 2.36 nM, the majority of kininase activity in rat urine
Table 2. Effects of phosphoramidon and captopril on renal function (N = 6 per Group)
H Ill IV
I Phosphoramidon Phosphoramidon Captopril
Group Control 110 /.Lg/hr/kg 330 pg/hr/kg 2 mg/hr/kg
Abbreviations are: C, control period; E, experimental period; R, recovery period.
a Significant difference within group (control period compared with experimental) by one—sided paired t-test with a Bonferroni adjustment (alpha
= 0.0125).b and Indicates a statistically significant change from control to experimental period (is) among the four groups (ANOVA, alpha = 0.05) and
results of pairwise comparisons (Tukey's test). Groups indicated with b differ from control (Group I). The group indicated by ' differ from
phosphoramidon 110 and from phosphoramidon 330 (except for kinins where captopril differed only from phosphoramidon 330). No other pairwise
differences were observed.
ci Determined in urine with added bradykinin substrate,
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was due to NEP. However, one should not directly extrapolate
these in vitro results to in vivo situations since the kinetics of
the reaction of NEP with the endogenous kinins may be altered
by many other factors (competitive substrates, electrolyte
concentrations, pH, etc.).
Infused phosphoramidon decreased urinary kininase activity
at the dose used. It completely abolished NEP and decreased
kininase I and II activities. It could be that phosphoramidon is
concentrated by the nephron, and at high concentrations, it can
partially inhibit both kininase I and II. Kinin excretion, UV and
UNaV were increased by phosphoramidon. Because of the
unchanged GFR and RBF, these effects are probably not due to
changes in renal hemodynamics, but rather to changes in renal
tubular reabsorption. However, we did not measure blood—flow
distribution. The increase in UV and UNaV may be caused by
increased intrarenal kinins due to inhibition of NEP by phos-
phoramidon. Inhibition of kininase II may play some role.
However, inhibition of kininase II by captopril produced a
much smaller increase in urinary kinins. Thus, it could be that
the effect of phosphoramidon is due to inhibition of kininase I.
Yet in urine, kininase I represents approximately 10% of the
total kininase activity. Phosphoramidon in vivo inhibited 50%
of this activity (or 5% of the total kininase activity). On the
other hand, NEP represented approximately 70% of the total
kininase activity and phosphoramidon inhibited 90% of this
activity in vivo (or 63% of the total kininase activity). Thus,
inhibition of kininase I contributed much less (5%) than inhibi-
tion of the NEP (63%) to the total kininase activity. In addition,
we have unpublished evidence that MGTA (or kininase I
inhibitor) does not protect kinins in the isolated perfused
kidneys. Thus, we feel that it is reasonable to assume that in the
rat, NEP plays a major role in the catabolism of kinins. This
effect can be direct or indirect via prostaglandins release.
However, the possibility that the renal effect of phosphorami-
don is mediated by mechanisms other than the renal kal-
likrein—kinin system cannot be eliminated. Indeed NEP cleaves
a variety of active peptides, and phosphoramidon may inhibit
the cleavage of peptides other than bradykinin. Atriopeptin III,
for example, is rapidly degraded on the brush border of the
rabbit. Two of the three bonds cleaved are adjacent to phenyl-
alanine; thus NEP may also be an atriopeptin inactivator and
phosphoramidon may also potentiate atriopeptin action [261.
Captopril infusion caused similar changes but smaller than
those observed after phosphoramidon administration. '251-Tyr°-
bradykinin infused into the aorta did not appear in urine intact
in spite of the administration of phosphoramidon and captopril
inhibitors. Thus, infused kinin was still inactivated after the
glomerular filtration, probably on the brush border of the
proximal tubules.
The increase in urinary kinin excretion after phosphoramidon
administration must have originated from an increase in endog-
enous kinins released at the level of the distal tubules. The
granular portions of distal and cortical collecting tubules are
especially rich in kallikrein [27] which is excreted into the distal
tubule U]. Although in humans and in most animals, tissue
kallikreins release kallidin (Lys-bradykinin) in the rat, urinary
kallikrein [28] and renal kallikrein of the basolateral membrane
[29] release only the nonapeptide bradykinin. Distal tubules do
not have immunohistochemically detectable kininase II or NEP
in man [20], but kininase II was detected in the distal tubules in
hogs [7]. In addition, cultured dog distal tubular cells (MDCK
cell) contained not only kininase I and II activities, but also
NEP (Ura et al, to be published).
In conclusion, NEP has a major role in the catabolism of
kinins in vitro and in vivo. The increase in UNaV and UKV after
phosphoramidon administration may be due to inhibition of
intrarenal kinin destruction. However, other effects of phos-
phoramidon cannot be ruled out.
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